Connect with us

coronavirus

COVID-19: MEPs to quiz CEOs of vaccine companies

SHARE:

Published

5 years ago

on

We use your sign-up to provide content in ways you've consented to and to improve our understanding of you. You can unsubscribe at any time.

MEPs will debate how to increase capacity and improve delivery of COVID-19 vaccines with pharmaceutical companies and Commissioners Breton and Kyriakides.

On Thursday, Members of the Public Health (ENVI) and Industry (ITRE) committees will hear from representatives of the pharmaceutical industry involved in developing, manufacturing and deploying the EU’s portfolio of vaccines against COVID-19.

When: Thursday 25 February 2021, 16.00 – 19.00

Where: European Parliament in Brussels, Paul-Henri Spaak (3C050) and videoconference

The full agenda of the hearing is available here.

You can watch the hearing live here.

Media briefing

Advertisement

On Wednesday 24 February, at 11.30, the Parliament’s press service will organize a technical briefing for journalists ahead of the hearing, with ENVI Chair, Pascal Canfin (Renew, FR) and ITRE Chair, Cristian Bușoi (EPP, RO).

To register for the briefing, please send your name and media affiliation to [email protected].

Background

The European Parliament organised several debates in different committees as well as at plenary sessions on various aspects of the COVID-19 vaccination strategy. During the last plenary debate in February 2021, MEPs underlined that the EU must continue its concerted efforts to fight the COVID-19 pandemic and take urgent measures to ramp up vaccines production to meet citizens’ expectations.

According to the EU vaccination strategy, three vaccines against COVID-19 have been authorised for use in the EU following positive scientific recommendations by the European Medicines Agency (BioNTech-Pfizer, Moderna and AstraZeneca). Three additional contracts have been concluded and will allow vaccines to be purchased once they have proven to be safe and effective: Johnson & Johnson (an application for conditional marketing authorization has been submitted), Sanofi-GSK and CureVac (both under rolling review). Exploratory talks were also concluded with two companies, Novavax and Valneva.

More information 

Share this article:

Share this:
Related Topics:
EU Reporter publishes articles from a variety of outside sources which express a wide range of viewpoints. The positions taken in these articles are not necessarily those of EU Reporter. Please see EU Reporter’s full Terms and Conditions of publication for more information EU Reporter embraces artificial intelligence as a tool to enhance journalistic quality, efficiency, and accessibility, while maintaining strict human editorial oversight, ethical standards, and transparency in all AI-assisted content. Please see EU Reporter’s full A.I. Policy for more information.
Advertisement

Trending